Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Why A Stock dropped -3.47% Today — RQD Quant Desk Flash
Agilent Technologies Inc. (A) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (52% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is A stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Agilent Technologies Inc. (NYSE: A) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $174.87 (-3.47% 1D, market cap $49.30B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, A ranks #55 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does A compare to WAT and MTD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), A carries a Roarable B (72/100 RQD), trailing P/E of 39.2x, gross margin of 52.4%, and ROIC of 15.3%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for A?
▼
Per A's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001090872), Agilent Technologies Inc. generated $6.95B in revenue (+6.7% YoY), $1.30B in net income, and $1.15B in free cash flow against $12.81B in total assets and $2.66B in total debt. Key quantitative strengths: Strong cash generator (52% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 6.50 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
20D Institutional Volume Accumulation (±5.5% realized swing band)
Macro rate sensitivity & RSI-14 (52.5) create a -9 pt regime headwind
⚔️ Adversarial Opposing Case: Why the A Bull Thesis Could Fail
Even with a 72/100 (B) score, A faces multiple-compression risk if 39.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($165.49) or 200D SMA ($136.64) invalidates the momentum regime and cuts Target Base ($185.89) toward Bear Floor ($143.39).
Why A Stock dropped -3.47% Today — RQD Quant Desk Flash
Agilent Technologies Inc. (A) dropped -3.47% to $174.87, trading at 89% of its 52-week range ($108.35 – $182.99). High-quality cash engine (52% profit margin, 15% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 89% of its 52-week range ($108.35 – $182.99) with RSI-14 at 52.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±5.5% around $174.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 52.4% gross margin and $1.2B annual free cash flow.
Trefis report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Capitalize on cybercrime demand, AI-enabled analysis and advanced DNA sequencing, while using tariff insights to optimize sourcing and regional expansion.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Forensic Technologies a
SANTA CLARA, Calif., November 02, 2026--Agilent Technologies Inc. (NYSE: A) today announced the launch of the 5987A single quadrupole mass selective detector (MSD) with GC Assist, along with MassHunter 14 software. When
Scheduled RQD Strong Buys & Whale Accumulation Briefing (A Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
A Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on A today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for A. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (A)
1. Head-to-Head Health Care Peer Comparison (A vs. WAT, MTD, RVTY, AVTR)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Agilent Technologies Inc. (A) ranks #55 by composite RQD confidence (72/100, grade B) and #39 by equity capitalization ($49.30B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with A at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| A
ACTIVE
Agilent Technologies Inc. | B | 72/100 | 39.2x | 52.4% | 15.3% | -3.47% | $49.30B | Benchmark Subject |
| WAT Waters Corporation | B | 72/100 | 73.4x | 59.3% | 16.8% | -3.61% | $45.46B | /wat-vs-a → |
| MTD Mettler-Toledo International Inc. | B+ | 78/100 | 39.6x | 59.4% | 30.4% | -2.55% | $33.56B | /mtd-vs-a → |
| RVTY Revvity Inc. | C | 65/100 | 76.7x | — | 3.1% | -5.30% | $17.52B | /rvty-vs-a → |
| AVTR Avantor Inc. | D+ | 56/100 | — | 32.7% | -2.1% | -3.78% | $10.88B | /avtr-vs-a → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0001090872In its most recent audited fiscal period (FY2025, filed 2025-10-31), Agilent Technologies Inc. (A) reported GAAP revenue of $6.95B (+6.7% vs. FY2024 revenue of $6.51B , and +1.7% cumulative change since FY2023) , GAAP net income of $1.30B, operating cash flow of $1.56B, and free cash flow of $1.15B (-16.1% YoY). On the balance sheet, A closed FY2025 with $12.81B in total assets against $2.66B in total debt (Altman Z-Score: 6.50, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-10-31 | $6.95B | $1.30B | $1.56B | $1.15B | $12.81B | $2.66B |
| FY2024 (FY) | 2024-10-31 | $6.51B | $1.29B | $1.75B | $1.37B | $11.91B | $2.65B |
| FY2023 (FY) | 2023-10-31 | $6.83B | $1.24B | $1.77B | $1.46B | $28.09B | $6.57B |
3. A Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs A stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Agilent Technologies Inc. (NYSE: A) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $174.87 (-3.47% 1D, market cap $49.30B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, A ranks #55 in composite RQD confidence.
How does A compare to WAT and MTD in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), A carries a Roarable B (72/100 RQD), trailing P/E of 39.2x, gross margin of 52.4%, and ROIC of 15.3%. By comparison, WAT (Waters Corporation) holds a B grade (72/100 RQD, P/E 73.4x, ROIC 16.8%, cap $45.46B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for A?
Per A's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001090872), Agilent Technologies Inc. generated $6.95B in revenue (+6.7% YoY), $1.30B in net income, and $1.15B in free cash flow against $12.81B in total assets and $2.66B in total debt. Key quantitative strengths: Strong cash generator (52% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 39x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is A trading relative to its 50-day, 200-day, and 52-week technical levels?
A last traded at $174.87 (-3.47% on volume of 2,756,523 shares), positioning the stock +5.67% above its 50-day simple moving average ($165.49) and +27.98% above its 200-day simple moving average ($136.64). Across its 52-week range of $108.35 to $182.99, A sits at the 89.1% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.5% ($165.25 to $184.49).
A Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is A stock moving today?
Why A Stock dropped -3.47% Today — RQD Quant Desk Flash. High-quality cash engine (52% profit margin, 15% return on capital) with steady institutional support.
A — Agilent Technologies Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, Agilent Technologies scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars break down as follows:
- Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 15.3% and an FCF yield of 2.26%. For an investor, the return on invested capital is solid, but the 2.26% free-cash-flow yield at the current price implies that the market is paying a premium for each dollar of cash generated, which is a valuation tradeoff rather than a discount.
- Whale 13F Flow: 18 / 20. The RQD rating describes this pillar as reflecting institutional accumulation and options positioning. This is the strongest pillar in the composite, suggesting that large institutional holders have been adding exposure. The underlying 13F holder records are not provided in the source data, so the magnitude of accumulation cannot be verified here.
- Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. A moderate score indicates insider and political-disclosure activity that is supportive but not decisively bullish. Individual transaction detail is not available in the source data.
- Macro Regime Fit: 12 / 20. Per the RQD rating, this pillar reflects a beta of 0.91 and sector sensitivity. A beta below 1.0 means the stock has historically moved less than the broad market, which can cushion drawdowns but also limits participation in strong market rallies. The score is middling, indicating neither a strong tailwind nor a clear headwind from the macro regime.
- Forensic Balance Sheet: 18 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 6.5, a Piotroski F-Score of 9/9, and Debt/Equity of 0.36. These are strong readings that point to low near-term financial distress risk and high reported financial quality.
Taken together, the composite suggests a company with a financially strong balance sheet and institutional support, offset by a premium valuation (trailing P/E of 39.2) and only moderate macro-regime alignment. The upside drivers are balance-sheet resilience and institutional interest; the valuation tradeoff is that the price already reflects much of the expected quality.
Snapshot
Business
Agilent Technologies Inc. is listed on the NYSE and classified under the Health Care sector. Per the company profile, it operates in the Biotechnology: Laboratory Analytical Instruments industry. The source data does not provide detail on specific products, customer segments, or revenue mix. Per the SEC financials, the company generated revenue of $6948.0M in FY 2025.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $6948.0M | $1479.0M | $1303.0M | N/A | $1152.0M | $1758.0M | $2657.2M |
| FY 2024 | $6510.0M | $1488.0M | $1289.0M | N/A | $1373.0M | $1467.0M | $2649.2M |
| FY 2023 | $6833.0M | $1350.0M | $1240.0M | N/A | $1464.5M | N/A | $6572.9M |
Per the market data, gross margin is 52.4%, operating margin 21.3%, and net margin 18.8%, with ROIC of 15.3%. Per the Roarable RQD rating, the Altman Z-Score is 6.5 and the Piotroski F-Score is 9/9, both pointing to strong financial health. Debt/Equity is 0.36 per the RQD rating. Reported debt was $2657.2M in FY 2025 against cash of $1758.0M, and FY 2023 debt is reported at $6572.9M with cash not available in source data. Revenue moved from $6833.0M (FY 2023) to $6510.0M (FY 2024) and back to $6948.0M (FY 2025), while operating income and net income stayed in a narrow band.
Recent Catalysts & News Wire Analysis
The news wire contains six items, all tagged to A. Headlines describe market action and outperformance (Yahoo Finance, MarketWatch), a Trefis note on management raising expectations, a Benzinga long-horizon return piece, a Yahoo Finance item on the opening of an energy materials research center, and a Simply Wall St forecast piece. Items are flagged GREEN (catalyst) or YELLOW (market wire). The source data does not include the body text of these articles, so the substance of the catalysts cannot be independently verified. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. An investor should note that the absence of mapped links means this brief cannot assess second-order ripple effects from supplier or customer disruptions.
Open Questions
- What are the specific products and end-markets driving the FY 2025 revenue of $6948.0M, and how is revenue mix distributed?
- Why is FY 2025 EPS and FY 2024 EPS reported as N/A, and what is the reported diluted share count?
- What explains the swing in reported debt between FY 2023 ($6572.9M) and FY 2024–2025 (roughly $2.6B), and what is FY 2023 cash?
- What do the institutional 13F filings and Form 4 insider transactions specifically show, given that the holders section is empty?
- Do analyst consensus ratings and price targets exist, given that the analyst data section is empty?
A Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Agilent Technologies Inc. (A) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agilent Technologies Inc. (A) market action, institutional positioning, and fundamental catalysts.
A Bull vs. Bear Conversation Board — What's Your Call at $174.87?
🔥 Official Bull vs. Bear Debate: Is A (B • RQD 75/100) a Buy at $181.15?
Welcome to the A (Agilent Technologies Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Laboratory Analytical Instruments. Bulls point to capital efficiency (15.3% ROIC), while bears focus on valuation multiple compression (39.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on A — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on A, but look at what you are paying: 39.2x trailing P/E with 52.4% gross margins. Unless Agilent Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
A cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on A, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $181.15 (52-wk range $108.35 - $182.99), any beat on forward guidance forces shorts and underweight funds to chase.